Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492141 · ClinicalTrials.gov registry record · Phase 1
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00492141: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00492141 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00492141, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the feasibility and toxicity profile of administering liposomal 9-Nitro-20-(S)-Camptothecin (L9-NC) by aerosol alone and in combination with temozolomide. 2. To determine the effectiveness of L9-NC given by aerosol in combination with temozolomide in patients with solid tumors involving the lungs.
Interventions
- DRUG Temozolomide
- DRUG L9-NC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492141
The ClinicalTrials.gov registry entry for NCT00492141 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00492141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492141 about?
NCT00492141 is a clinical study titled "Aerosol L9-NC and Temozolomide in Ewing's Sarcoma". Primary Objectives: 1. To determine the feasibility and toxicity profile of administering liposomal 9-Nitro-20-(S)-Camptothecin (L9-NC) by aerosol alone and in combination with temozolomide. 2. To determine the effectiveness of L9-NC given by aerosol in combination with temozolomide in patients wit...
What is the current status of trial NCT00492141?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2006-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00492141?
The interventions under investigation include: Temozolomide (DRUG), L9-NC (DRUG).
Who is sponsoring clinical trial NCT00492141?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.